Finland, a Global Testbed for Personalized Cancer Research? FI/OTHE/1709/0033

General Manager Roche Oy Maturin Tchoumi General Manager Roche Oy FI/ROCH/1702/0031 FI/ROCH/1704/0061(1)

Driving discovery GLOBAL #1 investor in healthcare R&D EUROPE 4.192 billion CHF total investment in R&D in 2016 924 scientists within pRED across Region Europe in 2017 GLOBAL #1 investor in healthcare R&D #7 investor in R&D (all industries) 9.915 billion CHF invested in R&D in 2016 #1 provider of cancer medicines A biotech leader – over 120 years of scientific research at our core Decentralised structure – enabling local markets to leverage local insights Leader in personalised healthcare - combine strengths of Pharmaceuticals and Diagnostics

Finland, a Global Testbed for Personalized Cancer Research? Mallimaa 2020 Finland, a Global Testbed for Personalized Cancer Research?

Healthcare mega trends Increased development spend, accelerated development timelines and increased complexity of science Industry is evolving: health and technology sectors will continue to converge. Personalized healthcare and big data will continue to transform medicine Europe is a cauldron of innovation, but with complex market, political and cultural archetypes all within one geography Price and cost pressures: European countries are combining negotiation strengths with innovative access strategies and pricing solutions Reduced product differentiation: only 25% of upcoming launches show significant differentiation / treat diseases with high burden Declining blockbuster model and rise in specialty medicines for rare diseases (75% of pharma pipelines) People continue to expect more. Stakeholders have access to the internet 24/7, resulting in an oversaturation of information and increase in demand Societal and payer expectations have shifted: prevention or cure over treatment: more caution around ‘true’ innovation

1 Patient, 1 Tumour 1 Profile, More Options Revolution of Cancer Care Cancer care is becoming more personalised, moving towards an individualised treatment plan for each patient Chemotherapy No / few biomarkers 1 Patient Group, 1 Biomarker, 1 Drug 1 Patient, 1 Tumour 1 Profile, More Options Advances in cancer biology are driving a future where cancer care is becoming increasingly personalised 6

Access meaningful data Realise value from insights Driving a more sustainable approach to R&D and improved patient outcomes More efficient and efficient R&D Improved patient outcomes Advanced analytics of integrated data Diagnostic Data Clinical Trial Data Real World Data Access meaningful data Create insights Realise value from insights 7

What makes Finland a potential Personalized Cancer Research? Mallimaa 2020 What makes Finland a potential Global Testbed for Personalized Cancer Research?

Finland 1. Benefit of homogeneous population 2. Tradition of high quality science, robust medical practice and infrastructure Top quality researchers with international networks Willingness for public-private collaboration (global pharma & hospital partnership agreements) One stop shops for collaboration (FICAN) Eight world-class biobanks, electronic medical records and registeries (cancer) Real world data opportunities (secondary data use legislation) 3. Early and full access to transformative medicine needs to be achieved